Abstract:Xin Yao, 1 Qingyu Wang, 1 Changge Han, 1 Jiaojiao Nie, 1 Yaotian Chang, 1 Lipeng Xu, 1 Bingya Wu, 1 Jingtian Yan, 1 Zhiyuan Chen, 1 Wei Kong, 1, 2 Yuhua Shi, 1 Yaming Shan 1, 2 1 National Engineering Laboratory for AIDS Vaccine, School of Life Sciences, Jilin University, Changchun, Jilin, 130012, People's Republic of China; 2 Key Laboratory for Molecular Enzymology and Engineering, The Ministry of Education, School of Life Sciences, Jilin University, Changchun, Jilin, 130012, People's Republic of China Correspondence: Yaming Shan, School of Life Sciences, Jilin University, 2699 Qianjin Street, Changchun, Jilin, 130012, People's Republic of China, Tel +86 133 2446 4361, Email Introduction: Broadly neutralizing antibodies (bNAbs) have the ability to neutralize a considerable breadth of genetically diverse human immunodeficiency virus (HIV) strains. Passive immunization can potentially provide protection against HIV infection in animal models. However, the direct antibody infusion effect is limited due to the short half-life and deficient immunogenicity of the antibody. As an alternative strategy, we propose the use of nano viral vectors, specifically the adeno-associated virus (AAV), to continuously and systematically produce bNAbs against HIV. Methods: Plasmids expressing bNAbs PG9, PG16, 10E8, and NIH45-46 antibodies were constructed, targeting three different epitopes of HIV. Additionally, the bNAbs gene mediated by rAAV8 was administered to generate long-term expression with a single injection. We established both single and combined immunization groups. The neutralizing activity of antibodies expressed in mice sera was subsequently evaluated. Results: The expression of bNAbs in BALB/c mice can last for > 24 weeks after a single intramuscular injection of rAAV8. Further studies show that neutralization of the HIV pseudovirus by sera from co-immunized mice with rAAV8 expressing 10E8 and PG16 was enhanced compared with mice immunized with 10E8 or PG16 alone. Conclusion: The prolonged expression of neutralizing antibodies can be maintained over long periods in BALB/c mice. This combined immunization is a promising candidate strategy for HIV treatment. Graphical Keywords: AAV delivery, HIV therapy, passive immunotherapy, combined immunotherapy Graphical The envelope glycoprotein (Env) of the human immunodeficiency virus (HIV) is the only virus-encoded protein present on the virion surface. The precursor of HIV Env is gp160, which is cleaved by furin into a heterodimer consisting of surface glycoprotein gp120 and transmembrane glycoprotein gp41. 1 Functional Env manifests as a trimer of gp120-gp41 heterodimers on the surface of infectious virions. 2 gp120 binds to cellular proteins CD4 and CCR5/CXCR4, whereas gp41 mediates the fusion between the virus and the host cell membrane. 3 Broadly neutralizing antibodies (bNAbs) are capable of recognizing a myriad of HIV-1 strains, including those less susceptible to surface alterations, and effectively decrease HIV-1 levels in the human body by inhibiting their replication. 4 These antibodies play a crucial role in preventing the virus from invading target cells, finalizing intracellular assembly, and releasing new viral particles. Furthermore, they increase viral clearance via phagocytosis 5 and eradicate infected cells through an FcγR-dependent mechanism. 6 Neutralizing antibodies also inhibit HIV-1 cell-to-cell spread. 7 The analysis of these antibodies revealed four major vulnerable sites of the Env virus, namely, the CD4 binding site (CD4bs), 8 gp120 interface trimerization glycan-dependent epitopes on variable loop 1 and variable loop 2 (V1/V2) on body apex 9 or variable loop 3 (V3), 10 and the membrane proximal outer region (MPER) of gp41. 11 Long-term treatment of HIV-1 infection necessitates repetitive injections due to the antibodies' short half-life within the body. 12 Adeno-associated virus (AAV) vectors exhibit potential as gene vectors for treating HIV-1 infection owing to their desirable gene delivery properties, nonpathogenic nature, and lack of immunotoxicity. 13,14 Moreover, utilizing the self-complementary double-stranded DNA form of the vector genome facilitates faster expression dynamics. 15 AAV vectors can be further optimized by engineering and fine-tuning viral capsids to enhance their transmission properties. 16 To date, at least 18 preclinical and clinical rAAV studies have been conducted related to HIV-1 res -Abstract Truncated-

Administration of nucleoside-modified mRNA encoding broadly neutralizing antibody protects humanized mice from HIV-1 challenge

Heterologous prime-boost vaccination drives early maturation of HIV broadly neutralizing antibody precursors in humanized mice

mRNA-LNP prime boost evolves precursors toward VRC01-like broadly neutralizing antibodies in preclinical humanized mouse models

mRNA-encoded HIV-1 Env trimer ferritin nanoparticles induce monoclonal antibodies that neutralize heterologous HIV-1 isolates in mice

Characterization of HIV-1 Nucleoside-Modified mRNA Vaccines in Rabbits and Rhesus Macaques

Short Carbon Nanotube-Based Delivery of mRNA for HIV-1 Vaccines

Delivery platforms for broadly neutralizing antibodies

Systemic Administration of Combinatorial Dsirnas Via Nanoparticles Efficiently Suppresses HIV-1 Infection in Humanized Mice

mRNA lipid nanoparticles expressing cell-surface cleavage independent HIV Env trimers elicit autologous tier-2 neutralizing antibodies

Combined Nano-Vector Mediated-Transfer to Suppress HIV-1 Infection with Targeted Antibodies in-vitro

Safety and tolerability of AAV8 delivery of a broadly neutralizing antibody in adults living with HIV: a phase 1, dose-escalation trial

Lipid nanoparticle-encapsulated mRNA antibody provides long-term protection against SARS-CoV-2 in mice and hamsters

HIV broadly neutralizing antibody escapability drives the therapeutic efficacy of vectored immunotherapy

mRNA Encoding a Bispecific Single Domain Antibody Construct Protects against Influenza A Virus Infection in Mice

Vaccination Induces Maturation of Diverse Unmutated VRC01-class Precursors to HIV-1 Broadly Neutralizing Antibodies in an Ig-humanized Mouse Model

Tandem Bispecific Neutralizing Antibody Eliminates HIV-1 Infection in Humanized Mice

A long-term stable cold-chain-friendly HIV mRNA vaccine encoding multi-epitope viral protease cleavage site immunogens inducing immunogen-specific protective T cell immunity

mRNA-LNP HIV-1 trimer boosters elicit precursors to broad neutralizing antibodies

Safety, pharmacokinetics and neutralization of the broadly neutralizing HIV‐1 human monoclonal antibody VRC01 in healthy adults

Vaccination induces maturation in a mouse model of diverse unmutated VRC01-class precursors to HIV-neutralizing antibodies with >50% breadth

Non-neutralizing antibodies targeting the immunogenic regions of HIV-1 envelope reduce mucosal infection and virus burden in humanized mice